Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative.

Published bySpencer Harvey Modified over 6 years ago

Similar presentations

Presentation on theme: "A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative."— Presentation transcript:

1 A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative Therapy: Trans Tasman Radiation Oncology Study TROG 03.07  Bryan H. Burmeister, MB, ChB, FFRad(T) SA, FRANZCR, MD, Michael Michael, MBBS(Hons), BSc(Hons), FRACP, MD, Elizabeth Burmeister, BN, MSc, Sharon Cox, A/Dip App Sc, Margot Lehman, MBBS, FRANZCR, Andrew Wirth, MBBS, MD, FRACP, FRANZCR, Keith Horwood, MBBS, FRACP, Giuseppe Sasso, MD, PhD, Barham Forouzesh, MBBS, FRACP, David Ball, MBBS, FRANZCR, MD  Journal of Thoracic Oncology  Volume 6, Issue 12, Pages (December 2011) DOI: /JTO.0b013e31822d53a9 Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1. Flow diagram of patients.
Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e31822d53a9) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2. Progression-free survival (p = 0.19).
Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e31822d53a9) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3. Overall survival (p = 0.25).
Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e31822d53a9) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4. FACT quality of life scores at baseline and 6 weeks posttreatment. Note: Higher score indicates increased QOL. TOI, trial outcome index; L, lung module. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e31822d53a9) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

6 FIGURE 5. FACT-L quality of life (lung) mean scores.
Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e31822d53a9) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative."

Similar presentations

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.
Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.
A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative.

A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative.
Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia  Arman Hasani, MBBS, FRACP, John M. Alvarez,

Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia  Arman Hasani, MBBS, FRACP, John M. Alvarez,
Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.
Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis  Sarah Cargnin, PhD,

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis  Sarah Cargnin, PhD,
Antibody Independent Microfluidic Cell Capture of Circulating Tumor Cells for the Diagnosis of Cancer  Eric Lim, MB, ChB, MD, MSc, FRCS, Andee Tay, BSc,

Antibody Independent Microfluidic Cell Capture of Circulating Tumor Cells for the Diagnosis of Cancer  Eric Lim, MB, ChB, MD, MSc, FRCS, Andee Tay, BSc,
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients.

A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients.
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes  Julie E. Bauman, MD, Michael.

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes  Julie E. Bauman, MD, Michael.
Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.

Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.
A Phase II Trial of Carboplatin and Weekly Topotecan in the First-Line Treatment of Patients with Extensive Stage Small Cell Lung Cancer  David R. Spigel,

A Phase II Trial of Carboplatin and Weekly Topotecan in the First-Line Treatment of Patients with Extensive Stage Small Cell Lung Cancer  David R. Spigel,
A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with.

A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with.
Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer

Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer
Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,
The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 
Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 
Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP 

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP 

Similar presentations

Ads by Google